Minireview: Endocannabinoids and their receptors as targets for obesity therapy

Endocrinology

Volumn 150, Issue 6, 2009, Pages 2531-2536

  De Kloet, Annette D ^a   Woods, Stephen C ^a,b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ADIPONECTIN; ANANDAMIDE; ANTIDEPRESSANT AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; DRONABINOL; ENDOCANNABINOID; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; PLACEBO; RIMONABANT; TARANABANT; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANXIETY; BODY WEIGHT; BRAIN; CALORIC INTAKE; CENTRAL NERVOUS SYSTEM; CHOLESTEROL BLOOD LEVEL; DEPRESSION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; ENERGY METABOLISM; FATTY LIVER; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIVER; MAJOR DEPRESSION; MENTAL DISEASE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; SLEEP DISORDER; TISSUE SPECIFICITY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; EATING; ENDOCANNABINOIDS; HUMANS; OBESITY; RECEPTORS, CANNABINOID; WEIGHT LOSS;

EID: 66649085214     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-0046     Document Type: Short Survey

References (52)

1. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF 2006 Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368:1660-1672 (Pubitemid 46048528)
2. Scheen AJ, Van Gaal LF 2007 Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes. Eur Heart J 28:1401-1402; author reply 1402 (Pubitemid 47425207)
3. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S 2005 Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397 (Pubitemid 40523733)
4. Addy C, Li S, Agrawal N, Stone J, Majumdar A, Zhong L, Li H, Yuan J, Maes A, Rothenberg P, Cote J, Rosko K, Cummings C, Warrington S, Boyce M, Gottesdiener K, Stoch A, Wagner J 2008 Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers. J Clin Pharmacol 48:418-427
5. Blüher M, Engeli S, Klöting N, Berndt J, Fasshauer M, Bátkai S, Pacher P, Schön MR, Jordan J, Stumvoll M 2006 Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55:3053-3060 (Pubitemid 44923642)
6. Devane WA, Axelrod J 1994 Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc Natl Acad Sci USA 91:6698-6701 (Pubitemid 24200729)
7. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R 1992 Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949 (Pubitemid 23026736)
8. Munro S, Thomas KL, Abu-Shaar M 1993 Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65 (Pubitemid 23305569)
9. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI 1990 Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564
10. Huang CC, Lo SW, Hsu KS 2001 Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol 532:731-748 (Pubitemid 32427887)
11. Schlicker E, Kathmann M 2001 Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22:565-572 (Pubitemid 33042646)
12. Rajesh M, Mukhopadhyay P, Bátkai S, Haskó G, Liaudet L, Huffman JW, Csiszar A, Ungvari Z, Mackie K, Chatterjee S, Pacher P 2007 CB2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 293:H2210-H2218 (Pubitemid 47605864)
13. Klein TW 2005 Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5:400-411 (Pubitemid 40685989)
14. Bermudez-Silva FJ, Sanchez-Vera I, Suárez J, Serrano A, Fuentes E, Juan-Pico P, Nadal A, Rodríguez de Fonseca F 2007 Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol 565:207-211 (Pubitemid 46782769)
15. Bermúdez-Silva FJ, Suárez J, Baixeras E, Cobo N, Bautista D, Cuesta-Muñoz AL, Fuentes E, Juan-Pico P, Castro MJ, Milman G, Mechoulam R, Nadal A, Rodríguez de Fonseca F 2008 Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 51:476-487
16. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB 1996 Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-87 (Pubitemid 26374593)
17. Di Marzo V, Bisogno T, Sugiura T, Melck D, De Petrocellis L 1998 The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronaland basophil-like cells: connections with anandamide. Biochem J 331(Pt 1):15-19 (Pubitemid 28163951)
18. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D 1994 Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686-691
19. Soria-Gómez E, Matias I, Rueda-Orozco PE, Cisneros M, Petrosino S, Navarro L, Di Marzo V, Prospéro-García O 2007 Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. Br J Pharmacol 151:1109-1116 (Pubitemid 47195529)
20. Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thöne-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U 2003 The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423-431 (Pubitemid 38063771)
21. DiPatrizio NV, Simansky KJ 2008 Activating parabrachial cannabinoid CB1 receptors selectively stimulates feeding of palatable foods in rats. J Neurosci 28:9702-9709
22. Di Marzo V, Matias I 2005 Endocannabinoid control of food intake and energy balance. Nat Neurosci 8:585-589 (Pubitemid 40594198)
23. Kirkham TC, Williams CM, Fezza F, Di Marzo V 2002 Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136:550-557 (Pubitemid 34717699)
24. Artmann A, Petersen G, Hellgren LI, Boberg J, Skonberg C, Nellemann C, Hansen SH, Hansen HS 2008 Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 1781:200-212
25. Williams CM, Kirkham TC 1999 Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 143:315-317 (Pubitemid 29204987)
26. Jamshidi N, Taylor DA 2001 Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 134:1151-1154 (Pubitemid 33097243)
27. Verty AN, McGregor IS, Mallet PE 2005 Paraventricular hypothalamic CB(1) cannabinoid receptors are involved in the feeding stimulatory effects of δ(9)-tetrahydrocannabinol. Neuropharmacology 49:1101-1109
28. Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G 2001 Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825 (Pubitemid 32303781)
29. Higgs S, Williams CM, Kirkham TC 2003 Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after δ(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. Psychopharmacology (Berl) 165:370-377
30. Melis T, Succu S, Sanna F, Boi A, Argiolas A, Melis MR 2007 The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food. Neurosci Lett 419:231-235 (Pubitemid 46755483)
31. Dipatrizio NV, Simansky KJ 2008 Inhibiting parabrachial fatty acid amide hydrolase activity selectively increases the intake of palatable food via cannabinoid CB1 receptors. Am J Physiol Regul Integr Comp Physiol 295:R1409-R1414
32. Thanos PK, Ramalhete RC, Michaelides M, Piyis YK, Wang GJ, Volkow ND 2008 Leptin receptor deficiency is associated with upregulation of cannabinoid 1 receptors in limbic brain regions. Synapse 62:637-642
33. Kola B, Farkas I, Christ-Crain M, Wittmann G, Lolli F, Amin F, Harvey-White J, Liposits Z, Kunos G, Grossman AB, Fekete C, Korbonits M 2008 The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS ONE 3:e1797
34. Tucci SA, Rogers EK, Korbonits M, Kirkham TC 2004 The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 143:520-523 (Pubitemid 39524268)
35. Huang H, Acuna-Goycolea C, Li Y, Cheng HM, Obrietan K, van den Pol AN 2007 Cannabinoids excite hypothalamic melanin-concentrating hormone but inhibit hypocretin/orexin neurons: implications for cannabinoid actions on food intake and cognitive arousal. J Neurosci 27:4870-4881 (Pubitemid 46699061)
36. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA 2003 Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 167:103-111 (Pubitemid 36535298)
37. Di Marzo V, Côté M, Matias I, Lemieux I, Arsenault BJ, Cartier A, Piscitelli F, Petrosino S, Alméras N, Després JP 2009 Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 52:213-217
38. Juan-Picó P, Fuentes E, Bermúdez-Silva FJ, Javier Díaz-Molina F, Ripoll C, Rodríguez de Fonseca F, Nadal A 2006 Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic β-cell. Cell Calcium 39:155-162
39. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S, Harvey-White J, Mackie K, Offertáler L, Wang L, Kunos G 2005 Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115:1298-1305 (Pubitemid 40629049)
40. Di Marzo V, Capasso R, Matias I, Aviello G, Petrosino S, Borrelli F, Romano B, Orlando P, Capasso F, Izzo AA 2008 The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. Br J Pharmacol 153:1272-1280
41. Karlsson M, Contreras JA, Hellman U, Tornqvist H, Holm C 1997 cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem 272:27218-27223 (Pubitemid 27452682)
42. Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G, Bianchi K, Rizzuto R, Bernante P, Federspil G, Vettor R 2007 The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 92:4810-4819 (Pubitemid 350223464)
43. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L, Festy F, Pasquali R, Roche R, Maj M, Pagotto U, Monteleone P, Di Marzo V 2006 Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91:3171-3180 (Pubitemid 44271774)
44. Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, Izzo AA, Di Marzo V 2008 Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 16:553-565
45. Gasperi V, Fezza F, Pasquariello N, Bari M, Oddi S, Agrò AF, Maccarrone M 2007 Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci 64:219-229 (Pubitemid 46155701)
46. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, Bátkai S, Marsicano G, Lutz B, Buettner C, Kunos G 2008 Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 118:3160-3169
47. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ 2004 Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 24:2708-2715 (Pubitemid 38380947)
48. Liu YL, Connoley IP, Wilson CA, Stock MJ 2005 Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 29:183-187 (Pubitemid 40188413)
49. Després JP, Golay A, Sjöström L 2005 Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134 (Pubitemid 41653104)
50. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J 2006 Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761-775 (Pubitemid 43244304)
51. Food and Drug Administration FDA Briefing document. NDA 21-888. Zimulti (rimonabant) Tablets, 20 mg. Sanofi Aventis. Advisory Committee - June 13, 2007. Available at http://www.fda.gov/ohrms/dockets/AC/07/briefing/2007-4306b1-fda- backgrounder.pdf (accessed August 9, 2007)
52. Isoldi KK, Aronne LJ 2008 The challenge of treating obesity: the endocannabinoid system as a potential target. J Am Diet Assoc 108:823-831